Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications (Q35676335)

9 August 2017

1 reference

title

Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications (English)

1 reference

magnetic resonance imaging

9 August 2017

1 reference

0 references

author name string

Peter Reimer

series ordinal

1

1 reference

9 August 2017

Günter Schneider

series ordinal

2

1 reference

9 August 2017

Wolfgang Schima

series ordinal

3

1 reference

9 August 2017

language of work or name

English

0 references

publication date

25 February 2004

1 reference

9 August 2017

1 reference

9 August 2017

14

1 reference

9 August 2017

4

1 reference

9 August 2017

559-578

1 reference

https://scigraph.springernature.com/pub.10.1007/s00330-004-2236-1

9 August 2017

0 references

cites work

Multihance clinical pharmacology: biodistribution and MR enhancement of the liver

1 reference

12 December 2020

Hepatocellular tumors: characterization with Mn-DPDP-enhanced MR imaging

1 reference

12 December 2020

Hepatic MRI with SPIO: detection and characterization of focal liver lesions

1 reference

12 December 2020

MR imaging evaluation of liver enhancement by Gd-EOB-DTPA in selective and total bile duct obstruction in rats: correlation with serologic, microcholangiographic, and histologic findings

1 reference

12 December 2020

Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: results of the U.S. Multicenter phase III clinical trials. Efficacy of early imaging

1 reference

12 December 2020

Hepatic transport of gadobenate dimeglumine in TR-rats

1 reference

12 December 2020

Comparison of gadobenate dimeglumine with gadopentetate dimeglumine for magnetic resonance imaging of liver tumors

1 reference

12 December 2020

Dynamic MR imaging of liver metastases with Gd-EOB-DTPA.

1 reference

12 December 2020

Gadolinium-ethoxybenzyl-DTPA, a new liver-directed magnetic resonance contrast agent. Absence of acute hepatotoxic, cardiovascular, or immunogenic effects.

1 reference

12 December 2020

Comparison between Gd-DTPA, Gd-EOB-DTPA, and Mn-DPDP in induced HCC in rats: a correlation study of MR imaging, microangiography, and histology

1 reference

12 December 2020

Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) as contrast agent for magnetic resonance imaging of the liver: mechanistic studies in animals.

1 reference

12 December 2020

Peripheral washout: a sign of malignancy on dynamic gadolinium-enhanced MR images of focal liver lesions.

1 reference

12 December 2020

Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging--a multicenter phase III clinical study.

1 reference

12 December 2020

New directions in the development of MR imaging contrast media

1 reference

12 December 2020

Volumetric mangafodipir trisodium-enhanced cholangiography to define intrahepatic biliary anatomy

1 reference

12 December 2020

Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers

1 reference

12 December 2020

MnDPDP enhanced magnetic resonance imaging of focal liver lesions

1 reference

12 December 2020

MnDPDP Enhancement Characteristics and Differentiation Between Cirrhotic and Noncirrhotic Livers

1 reference

12 December 2020

Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging

1 reference

12 December 2020

Mn-DPDP-enhanced MR imaging of malignant liver lesions: efficacy and safety in 20 patients

1 reference

12 December 2020

Pancreatic enhancement after low-dose infusion of Mn-DPDP

1 reference

12 December 2020

Unexpected MR-T1 enhancement of endocrine liver metastases with mangafodipir

1 reference

12 December 2020

Gadolinium-ethoxybenzyl-DTPA as a hepatobiliary contrast agent for use in MR cholangiography: results of an in vivo phase-I clinical evaluation

1 reference

12 December 2020

Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings

1 reference

12 December 2020

Preoperative detection of hepatocellular carcinoma: ferumoxides-enhanced versus mangafodipir trisodium-enhanced MR imaging

1 reference

12 December 2020

Soluble-type hepatobiliary contrast agents for MR imaging

1 reference

12 December 2020

Safety assessment of gadobenate dimeglumine (MultiHance): extended clinical experience from phase I studies to post-marketing surveillance

1 reference

12 December 2020

Mn-DPDP in MR imaging of pancreatic adenocarcinoma: initial clinical experience

1 reference

12 December 2020

Currently used non-specific extracellular MR contrast media

1 reference

12 December 2020

MRI of focal nodular hyperplasia (FNH) with gadobenate dimeglumine (Gd-BOPTA) and SPIO (ferumoxides): an intra-individual comparison

1 reference

12 December 2020

A toxicologic risk for using manganese complexes? A literature survey of existing data through several medical specialties

1 reference

12 December 2020

Cirrhosis of the liver: MR imaging with mangafodipir trisodium (Mn-DPDP)

1 reference

12 December 2020

Atypical focal nodular hyperplasia of the liver: imaging features of nonspecific and liver-specific MR contrast agents

1 reference

12 December 2020

Focal liver lesions: MR imaging with Mn-DPDP--initial clinical results in 40 patients

1 reference

12 December 2020

Clinical and cost effectiveness of a new hepatocellular MRI contrast agent, mangafodipir trisodium, in the preoperative assessment of liver resectability

1 reference

12 December 2020

Differentiation of hepatomas from nonhepatomatous masses: use of MnDPDP-enhanced MR images

1 reference

12 December 2020

Benign and malignant hepatocellular tumors: evaluation of tumoral enhancement after mangafodipir trisodium injection on MR imaging

1 reference

12 December 2020

Hepatobiliary MR imaging: first human experience with MnDPDP

1 reference

12 December 2020

Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging

1 reference

12 December 2020

Contrast-enhanced MR imaging of the liver

1 reference

12 December 2020

Characterization of liver lesions with mangafodipir trisodium-enhanced MR imaging: multicenter study comparing MR and dual-phase spiral CT.

1 reference

12 December 2020

Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging.

1 reference

12 December 2020

Liver contrast media for magnetic resonance imaging. Interrelations between pharmacokinetics and imaging.

1 reference

12 December 2020

Mn-DPDP enhancement patterns of hepatocellular lesions on MR images

1 reference

12 December 2020

MnDPDP-enhanced MRI vs dual-phase spiral CT in the detection of hepatocellular carcinoma in cirrhosis

1 reference

12 December 2020

Hepatic hemangiomas: a multi-institutional study of appearance on T2-weighted and serial gadolinium-enhanced gradient-echo MR images

1 reference

12 December 2020

Gadobenate dimeglumine (Gd-BOPTA). An overview

1 reference

12 December 2020

Manganese-DPDP as a Hepatobiliary Contrast Agent in the Magnetic Resonance Imaging of Liver Tumors: Results of Clinical Phase II Trials in Germany Including 141 Patients

1 reference

12 December 2020

Optimal dose of hepatobiliary contrast agent for MR cholangiography: experimental study in rats

1 reference

12 December 2020

Focal liver lesions: characterization with nonenhanced and dynamic contrast material-enhanced MR imaging.

1 reference

12 December 2020

Primary liver neoplasms: MR imaging with pathologic correlation

1 reference

12 December 2020

Tolerability and utility of mangafodipir trisodium injection (MnDPDP) at the dose of 5 mumol/kg body weight in detecting focal liver tumors: results of a phase III trial using an infusion technique

1 reference

12 December 2020

Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system

1 reference

12 December 2020

Hypervascular hepatic lesions: dynamic and late enhancement pattern with Gd-BOPTA.

1 reference

12 December 2020

Detection of bile duct leaks using MR cholangiography with mangfodipir trisodium (Teslascan).

1 reference

12 December 2020

Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications

1 reference

12 December 2020

Evaluation of focal pancreatic masses: comparison of mangafodipir-enhanced MR imaging and contrast-enhanced helical CT.

1 reference

12 December 2020

Preclinical evaluation of MnDPDP: new paramagnetic hepatobiliary contrast agent for MR imaging

1 reference

12 December 2020

Gadobenate dimeglumine-enhanced magnetic resonance imaging of intracranial metastases: effect of dose on lesion detection and delineation

1 reference

12 December 2020

Contrast-enhanced MR imaging of the liver: comparison between Gd-BOPTA and Mangafodipir

1 reference

12 December 2020

Diagnostic efficacy of MnDPDP in MR imaging of the liver. A phase III multicentre study

1 reference

12 December 2020

MRI characteristics in focal hepatic disease before and after administration of MnDPDP: discriminant analysis as a diagnostic tool

1 reference

12 December 2020

MRI with mangafodipir trisodium in the detection and staging of pancreatic cancer

1 reference

12 December 2020

Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison

1 reference

12 December 2020

MnDPDP-enhanced MR imaging of the liver. Correlation with surgical findings

1 reference

12 December 2020

3DFT-FISP MRI with gadopentetate dimeglumine in differential diagnosis of small liver tumors

1 reference

12 December 2020

Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence

1 reference

12 December 2020

Biliary excretion and pharmacokinetics of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging in the rat

1 reference

12 December 2020

Hepatocellular carcinoma: MR imaging with mangafodipir trisodium (Mn-DPDP)

1 reference

12 December 2020

Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging.

1 reference

12 December 2020

Metabolism and pharmacokinetics of MnDPDP in man

1 reference

12 December 2020

Comparison of in-phase and out-of-phase gradient recalled echo T1-weighted pulse sequence for MR imaging of malignant liver masses following administration of paramagnetic gadolinium-chelate

1 reference

12 December 2020

Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA

1 reference

12 December 2020

Functional hepatobiliary imaging with gadolinium-EOB-DTPA. A comparison of magnetic resonance imaging and 153gadolinium-EOB-DTPA scintigraphy in rats

1 reference

12 December 2020

Contrast-enhanced MRI of focal liver tumors using a hepatobiliary MR contrast agent: detection and differential diagnosis using Gd-EOB-DTPA-enhanced versus Gd-DTPA-enhanced MRI in the same patient

1 reference

12 December 2020

A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI.

1 reference

12 December 2020

Hepatic MR imaging with Mn-DPDP: safety, image quality, and sensitivity

1 reference

12 December 2020

Liver lesions: manganese-enhanced MR and dual-phase helical CT for preoperative detection and characterization comparison with receiver operating characteristic analysis

1 reference

12 December 2020

Liver metastases: improved detection with dynamic gadolinium-enhanced MR imaging?

1 reference

12 December 2020

10.1007/S00330-004-2236-1

Identifiers

DOI

1 reference

9 August 2017

1 reference